Mr J Meirion Thomas is a retired Professor of Surgical Oncology, he still consults patients privately in London and specialises in the treatment of sarcoma and melanoma.
Meirion is the former Lead Surgeon and at the Sarcoma and Melanoma Unit at The Royal Marsden Hospital. During his 30 years as a Consultant Surgeon, he has worked in most branches of surgical oncology but for the past decade has focused, almost exclusively, on the treatment of soft tissue sarcoma and malignant melanoma.
Soft Tissue Sarcoma
The Soft Tissue Sarcoma Unit at The Royal Marsden Hospital. is the largest in Europe and one of the largest in the World. More than 600 new patients are referred annually, the majority for consideration of surgical treatment. Working with colleagues within an expert Multi-Disciplinary Team, Meirion Thomas published extensively on this subject including a prestigious review article in the New England Journal of Medicine in 2005.
Meirion's unit was typically referred more than 200 new cases of malignant melanoma per annum, mostly for treatment of advanced disease. The Royal Marsden Hospital. is the only centre in the UK which offers isolated limb perfusion with Melphalan and tumour necrosis factor alpha. Mr Thomas and his team were the first to describe the use of carbon-dioxide laser vaporisation in the treatment of in-transit melanoma.
Research & Development
A large number of patients are also referred for treatment of primary cutaneous melanoma and over the past decade, Mr Thomas has emerged as one of the most prominent opponents of the sentinel lymph node biopsy procedure as currently practiced. He has argued in many publications that the procedure represents excessive and unnecessary surgery for most patients and that the procedure fails to offer any survival advantage for any legitimate subgroup of patients. The alternative treatment offered at the Royal Marsden Hospital is screening and regular surveillance of the lymph node basin by high-resolution ultrasound.